Wednesday, March 23 – Thursday, March 24, 2011 Washington, DC Metro Area The Liaison Capitol Hill 415 New Jersey Avenue, NW Washington, DC 20001 Molecular Diagnostics And the Changing Landscape is an […]
Global In Vitro Diagnostic Market Analysis
A new market research report on the In Vitro Diagnostic market is now available in the reportlinker.com catalogue.
Colon Cancer Screening made Simple
Women should be aware that they have several options for colon cancer screening, and not only the often-dreaded colonoscopy, according to a new report from the American College of Obstetricians and Gynecologists.
Cermed Corporation Develops Alternative to Traditional Pap Smear
Cermed Corporation is a medical devices company that has developed an apparatus for advanced diagnostic analysis of cervical tissue, which serves as a routine screening test for women’s cervical cancer. This unique […]
Provista Diagnostics
Provista Diagnostics, Inc., a Delaware company, is a privately held molecular diagnostics company offering diagnostic testing and reference clinical laboratory services tot he pharmaceutical and biotechnology industries. Additionally, the company is focused […]
EpiCept Corporation Announces Year End Results and Updates On Clinical Trials Surrounding Cancer Treatment
EpiCept Corporation recently announced operating and financial results for the year 2010, and provided an update on its key business initiatives.
Exosome Diagnostics Develops Unique Genetic Based Diagnostics
Exosome Diagnostics is a specialized bio-pharmaceutical company that develops a unique kind of genetic-based diagnostic tests. The company’s technological platform isolates from the blood micro-vesicles produced by cells, and then analyze the […]
NeoGenomics Reports Fourth Quarter and Full Year 2010 Results
FT. MYERS, Fla., Feb. 10, 2011 /PRNewswire/ — NeoGenomics, Inc. (OTC Bulletin Board: NGNM), a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter 2010 and fiscal year ended December 31, 2010.
